CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

BENGALURU, India, Jan. 16, 2025 /PRNewswire/ -- Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics laboratory in Bengaluru.

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

CRISPR-Cas9 pioneer presented with National Medal of Technology and Innovation in White House awards ceremony.

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...